Comparing momelotinib and ruxolitinib for myelofibrosis and low blood counts
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial compares two oral drugs, momelotinib and ruxolitinib, for people with myelofibrosis who have low blood cell counts. Both drugs aim to reduce an enlarged spleen and improve symptoms, and this study will see which one works better and with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have a myelofibrosis diagnosis (primary or after other blood conditions) confirmed by bone marrow biopsy within the last 4 years
- Have an enlarged spleen (at least 450 cm³ on an MRI or CT scan)
- Have a DIPSS risk score of Intermediate-1, Intermediate-2, or High
- Stop all myelofibrosis treatments (like hydroxyurea or interferon) at least 14 days before starting
- Have adequate kidney, liver, and blood cell function, and be able to take oral medications
- Not have had a prior stem cell transplant, JAK inhibitor treatment, or spleen removal
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs, ruxolitinib and ulixertinib, for people with myelofibrosis whose disease is not fully controlled by ruxolitinib alone. The goal is to see if adding ulixertinib can improve spleen enlargement, symptoms, or bone marrow changes.
This trial combines two drugs, bomedemstat and momelotinib, to treat myelofibrosis, a rare blood cancer. It aims to see if the combination helps improve blood counts and reduce symptoms when momelotinib alone isn't working well enough.
This trial tests whether adding a drug called interferon alfa-2b to the standard treatment ruxolitinib can help people with myelofibrosis. It may reduce spleen size and improve blood counts.
This trial tests whether adding TL-895 to ruxolitinib can improve outcomes in adults with myelofibrosis. It focuses on people who are not getting enough benefit from ruxolitinib or who need treatment as part of the study.
This study looks at how well momelotinib works in people with myelofibrosis who have an enlarged spleen. It checks the drug's effects in everyday medical practice, not in a strictly controlled lab setting.
This study tests whether a new drug called elritercept can help reduce the need for blood transfusions in adults with myelofibrosis (a bone marrow cancer) who are already taking ruxolitinib. The goal is to see if elritercept helps your body make more red blood cells naturally.
Hear when a new Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.